Month: April 2023

– Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter – – ODYSSEY Topline Results Expected in Q3 2024 – ALPHARETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today plans for ODYSSEY, a randomized, double-masked, parallel-group, active-controlled, multi-center Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD). The Company plans to open the trial for enrollment this quarter and expects topline results in Q3 2024. George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer,...

FREMONT, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (NASDAQ: ENVX), an advanced silicon battery company, today announced the pricing of $150.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2028 (the “Notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) (the “Offering”) and in a concurrent private placement under Section 4(a)(2) of the Securities Act. An entity affiliated with Thurman J. Rodgers, Chairman of Enovix, has agreed to purchase $10.0 million aggregate principal amount of the Notes in the concurrent private placement. The Notes purchased in the concurrent private placement are referred to as the “Affiliate Notes.” In addition, an...

CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), the leading Carbon Capture and Transformation (“CCT”) company, today announced that it will issue its first quarter 2023 financial results before the market opens on Monday, May 15, 2023. A conference call will be held that same day at 8:30 A.M. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session. The conference call may be accessed via a live webcast on a listen-only basis at https://ir.lanzatech.com/news-events/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software. To participate in the live teleconference: Domestic callers: 1-877-407-0789 International...

CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumabNEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes. “With the FDA approval of the humanized...

Company AnnouncementNet sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)COPENHAGEN, Denmark; April 18, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 2,264 million in the first quarter of 2023. Net trade sales were USD 1,191 million in the U.S. and USD 1,072 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize...

CENTREVILLE, Va., April 18, 2023 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company’s Critical Infrastructure segment has been selected by the Missouri Department of Transportation (MoDOT) as a member of the design-build team for the Bi-State Chester Bridge Design-Build project over the Mississippi River between Perryville, MO and Chester, IL to replace the existing aging and outdated truss bridge. Parsons, as a subcontractor to Ames Construction, will serve as lead designer to provide a unique 4-span, 3-tower cable stay bridge design that will minimize risk to navigation traffic on the river. “We are excited to partner with MoDOT, IDOT, and Ames Construction to enhance traveler safety and mobility by delivering innovative infrastructure solutions that will improve transportation throughout the...